IntelliCell BioSciences Announces Frederick Frank as Executive Advisor to Board of Directors
NEW YORK, May 10, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (OTCQB: SVFC.PK) announced today that Mr. Frederick Frank , Vice-Chairman of Peter J. Solomon Company, has joined the Company as an executive advisor to the Board of Directors.
Dr. Steven Victor , CEO of IntelliCell, stated "We are very pleased to have Mr. Frank join our organization and gain access to his biotechnology expertise and leadership. He has made a tremendous impact on our industry and specifically for the companies he has chosen to be affiliated with. We look forward to his counsel as we strive to achieve new landmarks in regenerative medicine."
Added Mr. Frank "Like many heralded advances in the life sciences field, the early promise and potential creates pronounced enthusiasm. Often the realization of that promise takes longer and is more complex than forecasted. And, inevitably, disappointment sets in. The promise of utilizing therapeutic stem cells is just such an example. But now it's here. Under the leadership of Dr. Steven Victor at IntelliCell BioSciences, the promise of tomorrow is a reality today."
About IntelliCell BioSciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous vascular cells (AAVC's) derived from the blood vessels in the adult adipose tissue. IntelliCell Biosciences has developed its own patent pending protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology licensing agreements and related service agreements with developers, physicians, physician practice groups, hospitals, ambulatory service centers and universities, both in the US and internationally.
About Mr. Frederick Frank
Mr. Frank joined Peter J. Solomon in 2009 from Barclays Capital where he was Vice Chairman. He began his investment banking career at Smith, Barney & Co. Inc. in 1958, where he attained the positions of Co-Head of Research, Vice President and Director. Subsequently he joined Lehman Brothers, Inc., in 1969, as a partner. At Lehman, Mr. Frank provided investment banking services to an extensive number of companies in the pharmaceutical, biotechnology, healthcare services, medical device and nutraceutical industries, and was involved in hundreds of financings, strategic alliances and merger and acquisition transactions in the global healthcare industry. Mr. Frank is a director of Landec Corporation, a publicly-traded material science company, and formerly a director of Pharmaceutical Product Development, Inc., a publicly-traded contract research organization. Mr. Frank previously served as Chairman of the Board of Epix Pharmaceuticals, Inc., a publicly-traded pharmaceutical company. He is Chairman of the National Genetics Foundation, a past director of the Salk Institute, a member of the Pharmaceutical Executive Magazine advisory board and the Journal of Life Sciences, the former Chairman of the Board of The Irvington Institute for Immunological Research, a former member of the Advisory Board of The Harvard School of Public Health, a past member of the advisory board of the Johns Hopkins Bloomberg School of Public Health and he serves on the Advisory Board of the Massachusetts Institute of Technology Center for Biomedical Innovation. He serves on the Yale School of Management Advisory Board. Mr. Frank holds a B.A. from Yale University and an M.B.A. from the Stanford Graduate School of Business.
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
IntelliCell BioSciences, Inc.
Rubenstein Investor Relations
Contact: Tim Clemensen
Email Contact: TClemensen@rubensteinir.com
SOURCE IntelliCell BioSciences, Inc.
More by this Source
IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
Dec 10, 2012, 14:24 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.